SpliceBio, a clinical-stage company developing genetic medicines through protein splicing to treat diseases caused by mutations in large genes, announced that Don Munoz has joined the company as Chief Financial Officer. Based in Boston, Munoz is an experienced biotechnology finance executive with extensive expertise in financial strategy, corporate development, and operations, supported by a strong background in healthcare investment banking.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
Miquel Vila-Perelló, Ph.D., CEO and Co-Founder of SpliceBio, stated that as the company advances its lead program, SB-007 for Stargardt disease, and continues to expand its pipeline, strengthening financial leadership is a top priority. Vila-Perelló noted that Munoz’s experience in guiding biotech companies through clinical execution, capital formation, and strategic growth will be critical as SpliceBio enters its next phase and works to create long-term value for patients and shareholders.
Before joining SpliceBio, Munoz served as CFO of Aurion Biotech, helping to lead the company’s acquisition by Alcon in March 2025. He previously held the CFO position at NuCana, overseeing its $114 million initial public offering and an $80 million follow-on financing. Munoz also served as Group CFO at Noxxon Pharma. Earlier in his career, he held senior roles in healthcare investment banking, including Managing Director and Head of Medical Technology Investment Banking at Cowen & Company and Leerink Partners, as well as leadership roles at Deutsche Bank and Alex. Brown & Sons. He earned a BA from Dartmouth College and an MBA from Columbia Business School.
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
Munoz expressed enthusiasm about joining SpliceBio, emphasizing that the company’s innovative genetic medicines platform addresses areas still underserved by current therapies. He highlighted the company’s strong clinical progress and leadership team, stating that he looks forward to supporting SpliceBio’s growth and contributing to long-term success that benefits patients worldwide.
This appointment reinforces SpliceBio’s commitment to advancing its pipeline efficiently while ensuring financial and strategic stability during a pivotal stage of clinical development.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
